Autotransfusion Devices Market is predicted to reach USD 0.5 billion at a CAGR of 5.20% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Autotransfusion Devices Market”.

The autotransfusion devices market is estimated to register a CAGR of 5.20% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global autotransfusion devices market - Terumo Corporation, Fresenius Kabi AG, Haemonetics Corporation, Medtronic, Stryker, LivaNova PLC, Atrium Medical Technologies, and Advancis Surgical.

Market Highlights

The global autotransfusion devices market is accounted to register a CAGR of 5.20% during the forecast period and is estimated to reach USD 0.5 billion by 2032.

One of the main factors propelling the autotransfusion devices market's growth is the increasing global prevalence of cardiovascular disorders. The World Health Organization estimates that around 17.9 million deaths annually worldwide are attributable to CVDs, or about 31% of all deaths. Because autotransfusion devices have no risk of isosensitization and lower the risk of infectious disease transmission, they are becoming increasingly popular. Additionally, rising investments in the healthcare sector in emerging nations are anticipated to fuel the market for autotransfusion devices.

Segment Analysis

The global autotransfusion devices market has been segmented into product type and end-user.

On the basis of product type, the market is segmented into On-pump Transfusion Device and Off-pump Transfusion Device. The off-pump transfusion devices segment was attributed to holding the largest market share in 2023 because it is regarded to be safer than the conventional method, is easier to use, and doesn't cause blood loss during transfusion.

Based on end-user, the global autotransfusion devices market has been segmented into Hospitals, Ambulatory Surgical Centers, and Cardiac Research Centers. The hospitals segment was expected to hold the largest market share in 2023, ascribed to the rise in cardiac and obstetrical/gynecological operations performed in hospitals. The adoption of autotransfusion devices in hospitals is anticipated to be boosted by a few factors, including the development of the healthcare infrastructure in developing nations and the rise in the number of advanced healthcare facilities. This will accelerate the growth of the hospital segment in the autotransfusion devices market.

Explore In-depth Details: Autotransfusion Devices Market Research Report

Regional Analysis

The global autotransfusion devices market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The Europe autotransfusion devices market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The autotransfusion devices market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World autotransfusion devices market comprises the Middle East, Africa, and Latin America.

The largest market share for autotransfusion devices was maintained by the North American regional sector because of improved medical facilities and infrastructure, growth in patients with orthopedic and cardiovascular conditions, and an aging population, which increases the likelihood of organ transplantation. Additionally, it is anticipated that the region's accessibility to reasonably priced autotransfusion devices will encourage market growth.

Moreover, the Europe market has been persistently growing over the forecast period. The growing need for improved healthcare infrastructure and the increased need for blood transfusions during surgeries are driving the region's autotransfusion devices market growth. Manufacturing is a major industry in the UK, which contributes to the increase in demand for autotransfusion devices.

Additionally, Asia Pacific is anticipated to experience the quickest growth over the forecast period. The market has grown as a result of the entry of new competitors and increased awareness of cell salvage technologies. The majority of the developed countries in the region have adopted autotransfusion techniques, devices, and consumables due to government emphasis on the lower risk of transfusion-transmitted infections.

Furthermore, the rest of the world's autotransfusion devices market is divided into the Middle East, Africa, and Latin America. Emerging markets like LAMEA are anticipated to grow significantly since government agencies are placing more emphasis on them due to the decreased risk of transfusion-transmitted infections. A substantial need for autotransfusion devices also exists in the region as a result of the increased incidence of cardiovascular diseases, such as heart attacks and strokes.

Key Findings of the Study

• The global autotransfusion devices market is expected to reach USD 0.5 billion by 2032, at a CAGR of 5.20% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market. Due to the introduction of new rivals and growing knowledge of cell salvage technologies, the market has expanded.


• Based on product type, the off-pump transfusion devices segment was attributed to holding the largest market in 2023, with an approximate market share of 45–65%.


• Terumo Corporation, Fresenius Kabi AG, Haemonetics Corporation, Medtronic, Stryker, LivaNova PLC, Atrium Medical Technologies, and Advancis Surgical are the key market players.